Literature DB >> 12834563

Diet, Weight Loss, and Cardiovascular Disease Prevention.

George A. Bray1, Donna H. Ryan, David W. Harsha.   

Abstract

Body weight, like cholesterol and blood pressure, are continuous variables. Overweight results when energy intake as food exceeds energy expenditure from exercise for a considerable period of time. When body weight becomes sufficiently high, it poses a risk to cardiovascular and metabolic health. The types of treatments considered by the physician and discussed with a patient should be based on this risk-benefit assessment. The body mass is the basic measurement for this assessment, and should be part of the "vital signs" when a patient is first evaluated by the medical staff. When the body mass index (BMI) is below 25 kg/m(2), there is little risk from the body weight, but because obesity is a "stigmatized" condition, many patients, particularly women, desire to lose weight even within the normal range. For this purpose, a high-quality diet like the Dietary Approaches to Stopping Hypertension (DASH) diet at a reduced-calorie intake would be our recommendation. When the BMI is above 25 kg/m(2), patients deserve dietary advice, but in addition to a reduced-calorie DASH-like diet, this is a place to consider using "portion-control" strategies, such as the nutrition labels that manufacturers provide on canned and frozen foods to guide patients in reducing calorie intake. In overweight individuals at high risk (ie, those with a BMI above 30 kg/m(2) or impaired glucose tolerance, hypertension, or the metabolic syndrome), the use of orlistat or sibutramine along with diet, exercise, lifestyle changes, and portion control should be considered. When the BMI is above 35 kg/m(2), bariatric surgery should also be discussed as an option for the "at-risk" individual. Evidence reviewed here shows that modest weight losses of 5% to 10% can reduce the risk of conversion from impaired glucose tolerance to diabetes and can maintain lower blood pressure over extended periods. All of the approaches described above can produce weight losses of this magnitude.

Entities:  

Year:  2003        PMID: 12834563     DOI: 10.1007/s11936-003-0025-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  27 in total

1.  Randomized, double-blind trial of chitosan for body weight reduction.

Authors:  M H Pittler; N C Abbot; E F Harkness; E Ernst
Journal:  Eur J Clin Nutr       Date:  1999-05       Impact factor: 4.016

Review 2.  Current and potential drugs for treatment of obesity.

Authors:  G A Bray; F L Greenway
Journal:  Endocr Rev       Date:  1999-12       Impact factor: 19.871

3.  Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.

Authors:  S B Heymsfield; K R Segal; J Hauptman; C P Lucas; M N Boldrin; A Rissanen; J P Wilding; L Sjöström
Journal:  Arch Intern Med       Date:  2000-05-08

4.  Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.

Authors:  W P James; A Astrup; N Finer; J Hilsted; P Kopelman; S Rössner; W H Saris; L F Van Gaal
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

5.  Sibutramine produces dose-related weight loss.

Authors:  G A Bray; G L Blackburn; J M Ferguson; F L Greenway; A K Jain; C M Mendel; J Mendels; D H Ryan; S L Schwartz; M L Scheinbaum; T B Seaton
Journal:  Obes Res       Date:  1999-03

6.  Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.

Authors:  T A Wadden; R I Berkowitz; L G Womble; D B Sarwer; M E Arnold; C M Steinberg
Journal:  Obes Res       Date:  2000-09

7.  Orlistat in the long-term treatment of obesity in primary care settings.

Authors:  J Hauptman; C Lucas; M N Boldrin; H Collins; K R Segal
Journal:  Arch Fam Med       Date:  2000-02

8.  Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.

Authors:  T A Wadden; R I Berkowitz; D B Sarwer; R Prus-Wisniewski; C Steinberg
Journal:  Arch Intern Med       Date:  2001-01-22

9.  Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

Authors:  P A Hollander; S C Elbein; I B Hirsch; D Kelley; J McGill; T Taylor; S R Weiss; S E Crockett; R A Kaplan; J Comstock; C P Lucas; P A Lodewick; W Canovatchel; J Chung; J Hauptman
Journal:  Diabetes Care       Date:  1998-08       Impact factor: 19.112

10.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

View more
  2 in total

Review 1.  Early impact of bariatric surgery on type II diabetes, hypertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6,587 patients.

Authors:  Cristian Ricci; Maddalena Gaeta; Emanuele Rausa; Yuri Macchitella; Luigi Bonavina
Journal:  Obes Surg       Date:  2014-04       Impact factor: 4.129

2.  Self-Care Practice and Associated Factors among Hypertensive Patients in Ethiopia: A Systematic Review and Meta-Analysis.

Authors:  Adam Wondmieneh; Getnet Gedefaw; Addisu Getie; Asmamaw Demis
Journal:  Int J Hypertens       Date:  2021-04-09       Impact factor: 2.420

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.